arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ARDELYX, INC.

ARDX
$4.00 ▼ -0.88 (-17.97%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

ARDELYX, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $983.4M
Dividend Yield
Revenue Growth 27.5%
Op. Margin -34.7%
ROIC -9.3%
FCF / Share $-0.13
Trailing P/E
Price / Book 6.7x
FCF Yield
Debt / Equity 1.37
info Valuation on last close. End-of-day price, Aug 7, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$94.47M
↑ +27.5%
Net Income Profit after all expenses
$-37.60M
↑ +8.6%
Operating Margin Operating profit as % of sales
-34.7%
↓ -952.4% 15th
FCF / Share Free cash flow per share
$-0.13
↑ +19.1%
Long-Term Debt Long-term obligations
$203.52M
— +0.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
13
Returns
20
Financial Health
32
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters